Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome
Ellen K RitchieLeukemia Program, Weill Medical College of Cornell University and The New York Presbyterian Hospital, New York, NY, USAAbstract: The goals of treating older patients with myelodysplastic syndrome (MDS) are different than for younger patients. Few elderly patients are able to pursue an...
Guardado en:
Autor principal: | Ritchie EK |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/acfd2aea969745b295f77e7d57acbbd2 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Managing myelodysplastic syndromes in very old patients: a teaching case report
por: Niscola P, et al.
Publicado: (2013) -
Lymphocytic Infiltrate and p53 Protein Expression as Predictive Markers of Response and Outcome in Myelodysplastic Syndromes Treated with Azacitidine
por: Carlo Pescia, et al.
Publicado: (2021) -
Transitory response of a myelodysplastic syndrome with deletion of chromosome 5q to thalidomide. Report of one case
por: Palacios-Campos,Adriana, et al.
Publicado: (2020) -
Managing myelodysplastic symptoms in elderly patients
por: R Ria, et al.
Publicado: (2009) -
Phenotypic and functional changes of NK cells in patients with myelodysplastic syndrome and acute myeloid leukemia treated with hypomethylating drugs
por: D. I. Zhigarev, et al.
Publicado: (2021)